<DOC>
	<DOCNO>NCT00969306</DOCNO>
	<brief_summary>Chloroquine might well able increase overall survival small cell lung cancer sensitize cell resistant chemotherapy radiotherapy .</brief_summary>
	<brief_title>Chloroquine Anti-Autophagy Drug Stage IV Small Cell Lung Cancer ( SCLC ) Patients</brief_title>
	<detailed_description>Tumor hypoxia well-known factor negatively influence outcome many solid tumor , include small cell lung cancer . Hypoxic cell radio-resistant , chemo-resistant prone develop distant metastasis normoxic cell . One mechanism responsible survival therapy-resistant hypoxic cell ( macro- ) autophagy : phenomenon cell provide energy ( ATP ) digest cell-organelles . Chloroquine potent blocker autophagy demonstrate lab set dramatically enhance tumor response radiotherapy , chemotherapy even anti-hormonal therapy . Thus , chloroquine might well able increase overall survival small cell lung cancer sensitize cell resistant chemotherapy radiotherapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>Histologically cytologically confirm `` extensive disease `` ( Stage T04 N03 M1 ) small cell lung cancer At least one measurable disease site , define lesion ≥ 1 cm unidimensionally CTscan . WHO performance status 02 Absolute neutrophil count least 1800/µl platelet least 100000/µl hemoglobin least 6.2 mmol/l . Calculated creatinine clearance least 60 ml/min Adequate hepatic function : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) institution ; ALT , AST , alkaline phosphatase ≤ 2.5 x ULN institution ( case liver metastases ≤ 5 x ULN institution ) No previous platinum chemotherapy topoisomeraseinhibitors SCLC . Life expectancy 6 month Willing able comply study prescription 18 year old Not pregnant breast feeding willing take adequate contraceptive measure study Ability give give write informed consent patient registration No mixed pathology , e.g . nonsmall cell plus small cell cancer No recent ( &lt; 3 month ) severe cardiac disease ( NYHA class &gt; 1 ) ( congestive heart failure , infarction ) No history cardiac arrythmia ( multifocal premature ventricular contraction , uncontrolled atrial fibrillation , bigeminy , trigeminy , ventricular tachycardia ) symptomatic require treatment ( CTC AE 4.0 ) , asymptomatic sustain ventricular tachycardia . Asymptomatic atrial fibrillation control medication allow . No cardiac conduction disturbance medication potentially cause : QTc interval prolongation medication require discontinuation treatment Congenital long QTsyndrome unexplained sudden death first degree relative 40 year age QTc interval &gt; 480 msec ( note : case screen ECG , ECG may repeat twice . If average QTinterval 3 measurement remain 480 msec , patient eligible ) Patients medication potentially prolongating QTinterval exclude QTinterval &gt; 460 msec ( Appendix , table 2 ) . Medication might cause QTprolongation Torsades de pointes tachycardia allow ( Appendix , Table 1 ) . Drugs risk prolongating QTinterval discontinue allow , however , close monitoring treat physician ( Appendix , table 2 ) . No uncontrolled infectious disease No active malignancy No major surgery ( exclude diagnostic procedure like e.g. , mediastinoscopy ) previous 4 week No treatment investigational drug 4 week prior study No chronic systemic immune therapy No know G6PD deficiency The opposite</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>